Related Experiment Video
Updated: Aug 10, 2026
10:02
Identification of Protein Interacting Partners Using Tandem Affinity Purification
Published on: February 25, 2012
Identification and immunoreactivity of proteins released from Streptococcus agalactiae
K Fluegge1, O Schweier, E Schiltz
1Department of Pediatrics and Adolescent Medicine, University Hospital Freiburg, Mathildenstrasse 1, 79106 Freiburg, Germany.
Summary
Researchers identified released proteins from Streptococcus agalactiae, finding they react with human sera. These proteins show promise as carrier proteins for new conjugate vaccines against neonatal infections.
Area of Science:
- Microbiology
- Immunology
- Vaccine Development
Background:
- Streptococcus agalactiae (Group B Strep) causes sepsis and meningitis in newborns.
- Current vaccines have low immunogenicity; protein-based strategies are being explored.
- Understanding virulence factors is crucial for effective vaccine design.
Purpose of the Study:
- To identify released proteins of Streptococcus agalactiae.
- To assess the immunoreactivity of these proteins with human sera.
- To evaluate their potential as carrier proteins in conjugate vaccines.
Main Methods:
- Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) to separate proteins.
- Western blot analysis to detect immunoreactivity with human sera.
- Identification of extracellular bacterial proteins.
Main Results:
- Several major released proteins of Streptococcus agalactiae were identified.
- Proteins previously known as surface-associated, like CAMP factor and enolase, were found to be released.
- Significant immunoreactivity of these released proteins with human sera was observed.
- Serotype-specific differences in protein profiles and immune responses were detected.
Conclusions:
- The identification of unexpected released proteins suggests potential secondary functions.
- Released Streptococcus agalactiae proteins demonstrate broad immunoreactivity, making them promising candidates for conjugate vaccine carriers.
- This finding supports the development of novel protein-based vaccines against Group B Strep infections.
